Current Utility and Future Applications of ctDNA in Colorectal Cancer

Daphne Day, Sophia Frentzas, Cameron Ashley Naidu, Eva Segelov, Maja Green

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Research

Abstract

Circulating tumour DNA (ctDNA) shows promise as a minimally invasive
biomarker with a myriad of emerging applications including early detection
and diagnosis, monitoring of disease and treatment efficacy, and identification
of actionable alterations to guide treatment. The potential utility of ctDNA in
colorectal carcinoma (CRC) is of particular interest given the limitations of current radiographic imaging and blood-based tumour markers in detecting disease and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical utility in CRC, a growing body of research highlights the potential of these novel biomarkers. This chapter provides an overview of the current evidence for employing ctDNA in CRC as well as previewing the future directions that these exciting technologies may take.
Original languageEnglish
Title of host publicationAdvances in the Molecular Understanding of Colorectal Cancer
EditorsEva Segelov
PublisherIn-Tech
Chapter4
Number of pages24
ISBN (Electronic)9781789850604
ISBN (Print)9781789850598
DOIs
Publication statusPublished - 6 Feb 2019

Cite this

Day, D., Frentzas, S., Naidu, C. A., Segelov, E., & Green, M. (2019). Current Utility and Future Applications of ctDNA in Colorectal Cancer. In E. Segelov (Ed.), Advances in the Molecular Understanding of Colorectal Cancer In-Tech. https://doi.org/10.5772/intechopen.82316
Day, Daphne ; Frentzas, Sophia ; Naidu, Cameron Ashley ; Segelov, Eva ; Green, Maja. / Current Utility and Future Applications of ctDNA in Colorectal Cancer. Advances in the Molecular Understanding of Colorectal Cancer. editor / Eva Segelov. In-Tech, 2019.
@inbook{73a4aca992634f059e5a349b290ba045,
title = "Current Utility and Future Applications of ctDNA in Colorectal Cancer",
abstract = "Circulating tumour DNA (ctDNA) shows promise as a minimally invasivebiomarker with a myriad of emerging applications including early detectionand diagnosis, monitoring of disease and treatment efficacy, and identificationof actionable alterations to guide treatment. The potential utility of ctDNA incolorectal carcinoma (CRC) is of particular interest given the limitations of current radiographic imaging and blood-based tumour markers in detecting disease and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical utility in CRC, a growing body of research highlights the potential of these novel biomarkers. This chapter provides an overview of the current evidence for employing ctDNA in CRC as well as previewing the future directions that these exciting technologies may take.",
author = "Daphne Day and Sophia Frentzas and Naidu, {Cameron Ashley} and Eva Segelov and Maja Green",
year = "2019",
month = "2",
day = "6",
doi = "10.5772/intechopen.82316",
language = "English",
isbn = "9781789850598",
editor = "Eva Segelov",
booktitle = "Advances in the Molecular Understanding of Colorectal Cancer",
publisher = "In-Tech",

}

Day, D, Frentzas, S, Naidu, CA, Segelov, E & Green, M 2019, Current Utility and Future Applications of ctDNA in Colorectal Cancer. in E Segelov (ed.), Advances in the Molecular Understanding of Colorectal Cancer. In-Tech. https://doi.org/10.5772/intechopen.82316

Current Utility and Future Applications of ctDNA in Colorectal Cancer. / Day, Daphne; Frentzas, Sophia; Naidu, Cameron Ashley; Segelov, Eva; Green, Maja.

Advances in the Molecular Understanding of Colorectal Cancer. ed. / Eva Segelov. In-Tech, 2019.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Research

TY - CHAP

T1 - Current Utility and Future Applications of ctDNA in Colorectal Cancer

AU - Day, Daphne

AU - Frentzas, Sophia

AU - Naidu, Cameron Ashley

AU - Segelov, Eva

AU - Green, Maja

PY - 2019/2/6

Y1 - 2019/2/6

N2 - Circulating tumour DNA (ctDNA) shows promise as a minimally invasivebiomarker with a myriad of emerging applications including early detectionand diagnosis, monitoring of disease and treatment efficacy, and identificationof actionable alterations to guide treatment. The potential utility of ctDNA incolorectal carcinoma (CRC) is of particular interest given the limitations of current radiographic imaging and blood-based tumour markers in detecting disease and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical utility in CRC, a growing body of research highlights the potential of these novel biomarkers. This chapter provides an overview of the current evidence for employing ctDNA in CRC as well as previewing the future directions that these exciting technologies may take.

AB - Circulating tumour DNA (ctDNA) shows promise as a minimally invasivebiomarker with a myriad of emerging applications including early detectionand diagnosis, monitoring of disease and treatment efficacy, and identificationof actionable alterations to guide treatment. The potential utility of ctDNA incolorectal carcinoma (CRC) is of particular interest given the limitations of current radiographic imaging and blood-based tumour markers in detecting disease and evaluating therapeutic benefit. While ctDNA has yet to demonstrate clinical utility in CRC, a growing body of research highlights the potential of these novel biomarkers. This chapter provides an overview of the current evidence for employing ctDNA in CRC as well as previewing the future directions that these exciting technologies may take.

U2 - 10.5772/intechopen.82316

DO - 10.5772/intechopen.82316

M3 - Chapter (Book)

SN - 9781789850598

BT - Advances in the Molecular Understanding of Colorectal Cancer

A2 - Segelov, Eva

PB - In-Tech

ER -

Day D, Frentzas S, Naidu CA, Segelov E, Green M. Current Utility and Future Applications of ctDNA in Colorectal Cancer. In Segelov E, editor, Advances in the Molecular Understanding of Colorectal Cancer. In-Tech. 2019 https://doi.org/10.5772/intechopen.82316